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Objective: To assess the antibacterial action of moxifloxacin on Haemophilus influenzaeand Moraxella catarrhalis using 
an in vitro pharmacodynamic model of infection. 
Methods: Serum concentrations in humans associated with doses of 400 mg once a day for 48 h were simulated and 
the antibacterial effect measured by the log change in viable count at intervals through the simulation compared to time 
zero and also the area under the bacterial kill curve (AUBKC). Wild- type strains of H. influenzae and M. catarrhalis with 
varying p-lactam susceptibilities (moxifloxacin MlCs 50.1 mg/L) and laboratory-generated mutants with moxifloxacin 
MlCs of 0.51.0 mg/L were tested. 
Results: H. influenzae strains with MlCs of 50.06 mg/L were eradicated by 12 h; strains with MlCs of 0.5-1.0 mg/L were 
eradicated by 24-36 h. M. catarrhalis strains with MlCs of 50.08 mg/L were eradicated by 24-36 h, while the less 
susceptible laboratory mutant (MIC 1.0 rng/L) was not eradicated even at 48 h. Although we used only a single dosing 
simulation, the AUC/MIC ratio was strongly related to the AUBKC. 
Conclusions: These data indicated that once daily dosing of moxifloxacin holds promise for the treatment of infection 
due to H. influenzae or M. catarrhalis but bacterial killing is related to MIC. 
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INTRODUCTION 
Haernophilus irlfluenzae and Moraxella catarrhalis are 
important causes of infective bacterial exacerbations in 
patients with chronic obstructive pulmonary disease 
(COPD). Such infections account for a significant 
healthcare burden, with over 250 000 cases treated in 
hospital and 16.3 million episodes overall at  a total cost 
in the UK of over /=l250 million a year [l]. In adult 
medical practice COPD exacerbations constitute a 
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much commoner reason for hospital admission than 
community-acquired pneumonia. As in the other 
major respiratory pathogen Streptococcus pneumoniae, the 
incidence of resistance in these species is an emergent 
problem. The percentages of M.  catarrhalir strains which 
produce p-lactamases and thus are ampicillin resistant are 
increasing in Europe and the USA [2]. In contrast, 
resistance to other commonly used antibacterials in 
COPD such as cephalosporins, tetracycline, co- 
trimoxazole and macrolides remains rare. p-Lactamase 
production by H. infuenzae is also increasing, as is the 
number of P-lactamase-negative ampicillin-resistant 
strains [3]; resistance to cephalosporins, quinolones and 
tetracyclines is uncommon but emerging in some 
patient groups or geographic areas [4-71. 
Quinolone antimicrobials such as ciprofloxacin 
and ofloxacin have been used to treat exacerbations of 
COPD due to Gram-negative bacteria, and the newer 
agents, such as clinafloxacin, gatifloxacin, grepaflox- 
acin, moxifloxacin and trovafloxacin, have equivalent 
or better in vitro activities against H. infuenzae and 
211. catarrhalis [8,9]. 
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However, it has become clear in recent times that 
the integration of indces of bacterial susceptibhty and 
pharmacokmetics to produce pharmacodynamic para- 
meters can help to predict the effectiveness of various 
dosing regimens. To this end, animal and in vitro 
pharmacodynamic models have been developed over 
the last 30 years [10,11]. 
In this study we explored the antibacterial activity 
of moxifloxacin by simulating serum concentrations 
associated with 400 mg once-daily dosing over a 48 h 
interval. Strains with varying moxifloxacin and p- 
lactam in vitro susceptibilities were used. Because of the 
rarity of clinical strains of H. itEfluenzae or M. catarrhalis 
with raised quinolone MICs, laboratory mutants were 
generated to aid pharmacodynamic analysis. 
MATERIALS AND METHODS 
A New Brunswick Bioflo 1000 (Hatfield, UK) in vitro 
model was used to simulate oral administration of 
400 mg of moxifloxacin every 24 h for 48 h. The model 
used has been described in detail before [12] and was 
modified by the addition of a second dosing chamber 
in order to simulate oral pharmacokinetics. Brain- 
heart infusion broth 75% (Unipath, Basingstoke, UK) 
supplemented with haemin 10 mg/L, P-nicotinamide 
adenine dinucleotide 10 mg/L and L-histidine 10 mg/L 
was found to support the growth of all isolates to a 
growth density of 107-10sCFU/mL after 18 h of 
incubation in the model. Viable counts were performed 
on nutrient agar plates containing 5% horse blood 
(Tissue Culture Services Microbiology, Buckingham, 
UK) and 1% magnesium chloride (British Drugs House, 
Poole, UK).  The following strains of H. inzuenzae were 
used: NCTC 11931 P-lactamase negative, moxifloxacin 
MIC 0.06 mg/L; NCTC 11931 p-lactamase positive, 
moxi-floxacin MIC 0.06 mg/L; SMH 4797, cefuroxime 
MIC 2 4  mg/L, moxifloxacin MIC 0.06 mg/L; SMH 
4797M, a mutant of 4797 (see below), moxifloxacin 
MIC I .O mg/L; SMH 5 100, imipenem MIC 2 4 mg/L, 
moxifloxacin MIC 0.06 mg/L; and strain 5100M, a 
mutant of 5100, moxifloxacin MIC 0.5 mg/L. Three 
M. catarrhalis strains were also employed: SMH 9567 
P-lactamase negative, moxifloxacin MIC 0.08 mg/L; 
strain SMH 9567M, a mutant of 9567, moxifloxacin 
MIC 1.0 mg/L; and strain 9573, p-lactamase positive, 
moxifloxacin MIC 0.1 mg/L. The strains with higher 
MICs were generated from the parent strains by the 
method of Dalhoff et al [13]. 
Moxifloxacin (Bay 12-8039) was obtained from 
Bayer AG, Wuppertal, Germany, and MICs were 
determined by the BSAC defined standard broth 
dilution method with the exception that 0.2 mg/L or 
0.02 mg/L steps in concentrations were used, not 
doubling dilutions [14]. 
The in vitro activity of moxifloxacin was tested in 
the model using the following target concentrations: 
1 h, 1.7mg/L; 2 h, 1.8mg/L; 3 h, 1.8mg/L; 4 h, 1.7 
mg/L; 6 h, 1.4 mg/L; 8 h, 1.3 mg/L; 12 h, 0.9 mg/L; 
24 h, 0.4 mg/L; 26 h, 2.3 mg/L; and 48 h, 0.5 mg/L 
(H.H. Stass, personal communication). Moxifloxacin 
was added to the dosing chamber at time zero and for 
a second time at 24 h. Samples were taken throughout 
the 48-h simulation at 0, 1, 2, 3, 4, 5, 6, 7, 10, 12, 22, 
24, 25,26, 27, 28, 29, 30, 31,34, 36, 46 and 48 h and 
viable counts quantified using a spiral plater (Don 
Whitley Spiral Systems, Shipley, UK). The minimum 
detection level was 2 X lo2 CFU/mL. Aliquots were 
also stored at -70°C for measurement of moxifloxacin 
by bioassay with Escherirhia coli NCTC 10418 as 
the indicator organism. The limit of detection was 
0.03 mg/L [15]. All simulations and killing curves were 
performed in triplicate, and isolates recovered from the 
dosing chamber had their moxifloxacin susceptibilities 
re-checked. 
The simulated moxifloxacin AUC was 24.4 mg/L 
per hour, with an elimination half-life of 8.8 h. Anti- 
microbial activity was assessed by calculating the log 
change in viable count from time zero at 12 h (Al2), 
24 h (A24), 36 h (A36) and 48 h (A48). In addition, the 
maximum reduction (Amax) and the area under the 
bacterial kill curve (AUBKC) at 24 h and 48 h were 
calculated. The AUBKC was calculated using the 
trapezoid rule. For pharmacodynamic analysis, the 
AUC/MIC ratios were related to the AUBKC at 24 h 
(AUBKC24) and 48 h (AUBKC18). This was done using 
a sigmoidal dose-response (variable slope) model 
(Graphpad Prizm, San Diego, Cahfornia, USA). 
RESULTS 
Pharmacokinetic data 
The mean k SD moxifloxacin concentrations in the 
model were 1.14k0.26 mg/L at 1 h, 2.0050.8 mg/L 
at 2 h, 1.76k0.58 mg/L at 3 h, 1.94k0.76 mg/L at 
4 h, 1.06+0.21 mg/L at 12 h, and 0.34k0.18 mg/L at 
24 h which is good agreement with the target values. 
Bacterial killing curves 
Moxifloxacin at the concentrations simulated resulted 
in rapid killing of all four strains of H. injuenzae with 
MICs of 0.06 mg/L, despite their varying p-lactam 
susceptibilities; the viable counts of all strains were 
reduced to below detectable limits before or at 12 h 
(Figure 1). In contrast, the mutant SMH 5100M, 
moxifloxacin MIC 0.5 mg/L, was not reduced below 
detectable limits until 24 h, and for strain 4797M, 
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Figure 1 Bactericidal effect of moxifloxacin, simulation dose of 400 mg every 24 h on H. inJuenzar: (a) strain NCTC 
11931, p-lactamase negative, moxifloxacin MIC 0.06 mg/L; (b) strain 4718, P-lactamase positive, moxifloxacin MIC 
0.06 mg/L; (c) strain 4797, cefuroxime resistant, moxifloxacin MIC 0.06 mg/L, and mutant strain 4797M, MIC 1.0 mg/L; 
(d) strain 5100, imipenem resistant, moxifloxacin MIC 0.06 mg/L and mutant strain 5100M, MIC 0.5 mg/L. 
moxifloxacin MIC 1.0 mg/L, viable counts were not 
reduced below 100 CFU/mL until after the second 
dose (Figure lc,d). These differences in antibacterial 
effect are reflected in A12, A24, A36, A48, Amax and 
AUBKC (Table 1). 
The pattern of antibacterial effects was sinlilar with 
M .  catarrhalis; both strains with MICs of 50.1 mg/L 
were reduced below the detectable limit by 34-36 h 
(Figure 2); the strain with an MIC of 1 mg/L was not 
eradicated even after a second drug exposure (Figure 2, 
Table 1). 
No change in moxifloxacin MIC was noted after 
drug exposure in the model. 
Pharmacodynamic analysis 
There was a clear relationship between MIC and 
AUBKC (Table 2) and a strong relationship between 
AUC24/MIC and AUBKC24, R2=0.79036, and 
AUC4s/MIC and AUBKC48, R2=0.79808 (Figure 3). 
As this was neither a dose-escalation nor a fractionation 
study, no further analysis was performed; time over 
MIC was strongly correlated with AUC24/MIC, cor- 
relation coefficient ~ 0 . 8 4 2 2 .  
DISCUSSION 
Moxifloxacin is known to have and MIC9o 













Table 1 Antibacterial action of moxifloxacin against H. infuenzae and M. catawhalis 
~ ~ ~~ ~~ ~~ 
Change in viable count AUBKC 
Moxifloxacin (log CFU/mL) at: (log CFU/mL. per hour) 
Species, strain MIC 
and resistances (mg/L) 1 2 h  24 h 36 h 48 h Max 0-24 0-48 
H. injuenrae 
NCTC P-lactamase negative 0.06 -6.440.2 -6.4k0.2 -6.420.2 -6.4k0.2 -6.440.2 25.1k5.3 25.12 5.3 
4718, P-lactamase positive 0.06 -5.520.5 -6.520.1 -6.520.1 -6.520.1 -6.540.1 32.452.7 32.422.7 
4797, cefuroxime resistant 0.06 -6.1 k0.5 -6.4'0.3 -6.420.3 -6.4k0.3 -6.4k0.3 35.425.6 35.425.6 
4797M. laboratory mutant 1.0 -3.2f1.0 -3.920.8 -6.2k0.1 -6.2'0.1 -6.240.1 77.6k17.2 83.1219.0 
5100, imipenern resistant 0.06 -6.4k0.1 -6.420.1 -6.4k0.1 -6.420.1 -6.440.1 16.61'6.1 16.126.1 
5100M. laboratory mutant 0.5 -3.621.4 -6.4k0.3 -6.5k0.1 -6.5k0.1 -6.540.1 63.3k13.2 63.5k13.6 
M .  catarrhah 
9567, 0-lactamase negative 0.08 -5.1f1.2 -5.821.1 -6.4k0.4 -6.450.4 -6.440.4 32.0220.9 34.9225.8 
9567M, laboratory mutant 1.0 -2.620.3 -3.8k0.3 -5.5f0.2 -4.321.0 -6.040.4 90.6k2.0 115.621.3 
9573, p-lactamase positive 0.1 -3.5 -5.220.6 -5.3rt-0.7 -5.3k0.7 -5.340.7 46.227.2 53.816.1 
0 0 d 
I 
0 12 24 36 48 
Time (h) - 9567m -- 9567m 




Figure 2 Bactericidal effect of moxifloxacin, simulated 
dose of 400 mg every 24 h on M.  catarrhah: (a) strain 
9567, P-lactamase negative, moxifloxacin MIC 0.08 mg/L, 
and mutant, MIC 1.0 mg/L; (b) strain 9573, p-lactamase 
positive, moxifloxacin MIC 0.1 mg/L. 
1 2 3 
log AUCzdMIC 
I 
0 :  I I 
1 2 3 
log A U G d M I C  
Figure 3 Moxifloxacin antibacterial activity against 
H. infuenzae and M. catarrhalis strains: relationship between 
AUBKC and AUC/MIC at 24 h and 48 h. 
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Table 2 Antibacterial effect of moxifloxacin against 
H. inflnenzae and M. caturrhalis: effect of MIC 
~ ~ 
AUBKC 
(log CFU/mL per hour) 
Moxifloxacin 
MIC (mg/L) 0-24 h 0-48 h 
~ 
1 0  08 (n=15) 28.3k11.2 28 9f12.8 
0 1-1.0 ( ~ = 6 )  54.9213.4 58.8210.7 
t 1.0 (n=6) 84.1+13 1 99 4f21.5 
values against H. inzuenzae  in the ranges 0.015-0.03 
and 0.03-0.06 mg/L respectively [9,13,16-181; a single 
wild-type strain with an MIC of > 2  mg/L has been 
reported [16]. In addition, moxifloxacin is rapidly 
bactericidal using time kill methodology at a fixed 
concentration equivalent to the maximum serum con- 
centration or at twice or 10 times the MIC: bactericidal 
activity was unaffected by the presence of serum 
[19,20]. Our data extend these findings using an in 
vitro continuous-culture pharmacodynamic model to 
simulate changing moxifloxacin concentrations and 
indicate a rapid bactericidal action against these strains 
of H. i n j u e n z a e  with MIC values of 10.06 mg/L. 
Laboratory-generated isogenic mutants with MICs of 
0.5 or 1.0 mg/L were killed less well, but counts were 
nevertheless reduced to below the limit of detection 
after two drug exposures. 
Moxifloxacin has marginally poorer in vitro 
activity against M.  catarrhalis than H. ir$rrenzae, with 
MICSO and MIC90 values in the ranges of 0.015-0.06 
and 0.03-0.12 mg/L respectively [9,16-181, but is 
bactericidal at clinically achievable serum concentra- 
tions [20]. In the in vitro model, M.  catarrhalis is rapidly 
killed when the MIC is 10.1 mg/L, although the less 
susceptible mutant was not eradicated over 48 h. It is 
clear that the eradication rate for both species is MIC 
dependent and strains with higher MICs are killed less 
effectively: an increase in simulated dose would almost 
certainly overcome this. 
The moxifloxacin pharmacokinetics modeled here 
were a result of early healthy volunteer data; presently, 
the CMAX of moxifloxacin after a 400 mg dose is 
thought to be in the range 2.8-3.4 mg/L and the AUC 
(mg/L per hour) 30.2-35.5, so the modeled profiles 
will tend to underestimate the activity of the drug 
[21,22]. As this study did not have a dose-escalation or 
fractionation design, it was not possible to use the data 
to determine which is the major pharmacodynamic 
predictor of antibacterial effect; however, the AUC/ 
MIC ratio was strongly related to bacterial killing, as 
indicated by the AUBKC. 
In conclusion, these simulations indicate that 
moxifloxacin administered at a dose of 400 mg every 
24 h has promising activity against H. i n f u e n z a e  and 
M. catarrhalis. 
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